Your browser does not allow JavaScript!
JavaScript is necessary for the proper functioning of this website. Please enable JavaScript or use a modern browser.
Open Science Slovenia
Open Science
DiKUL
slv
|
eng
Search
Browse
New in RUL
About RUL
In numbers
Help
Sign in
Dual effect of combined metformin and 2-deoxy-D-glucose treatment on mitochondrial biogenesis and PD-L1 expression in triple-negative breast cancer cells
ID
Repas, Jernej
(
Author
),
ID
Zupin, Mateja
(
Author
),
ID
Vodlan, Maja
(
Author
),
ID
Veranič, Peter
(
Author
),
ID
Gole, Boris
(
Author
),
ID
Potočnik, Uroš
(
Author
),
ID
Pavlin, Mojca
(
Author
)
PDF - Presentation file,
Download
(5,36 MB)
MD5: D80029C8980060DF6663C4C337DC4A3F
URL - Source URL, Visit
https://www.mdpi.com/2072-6694/14/5/1343
Image galllery
Abstract
Metformin and 2-deoxy-D-glucose (2DG) exhibit multiple metabolic and immunomodulatory anti-cancer effects, such as suppressed proliferation or PD-L1 expression. Their combination or 2DG alone induce triple-negative breast cancer (TNBC) cell detachment, but their effects on mitochondria, crucial for anchorage-independent growth and metastasis formation, have not yet been evaluated. In the present study, we explored the effects of metformin, 2DG and their combination (metformin + 2DG) on TNBC cell mitochondria in vitro. Metformin + 2DG increased mitochondrial mass in TNBC cells. This was associated with an increased size but not number of morphologically normal mitochondria and driven by the induction of mitochondrial biogenesis rather than suppressed mitophagy. 2DG and metformin + 2DG strongly induced the unfolded protein response by inhibiting protein N-glycosylation. Together with adequate energy stress, this was one of the possible triggers of mitochondrial enlargement. Suppressed N-glycosylation by 2DG or metformin + 2DG also caused PD-L1 deglycosylation and reduced surface expression in MDA-MB-231 cells. PD-L1 was increased in low glucose and normalized by both drugs. 2DG and metformin + 2DG reduced PD-1 expression in Jurkat cells beyond the effects on activation, while cytokine secretion was mostly preserved. Despite increasing mitochondrial mass in TNBC cells, metformin and 2DG could therefore potentially be used as an adjunct therapy to improve anti-tumor immunity in TNBC.
Language:
English
Keywords:
protein N-glycosylation
,
ER stress
,
AMPK
,
PD-1/PD-L1 axis
,
anchorage-independence
,
metformin
,
2-deoxy-D-glucose
,
triple-negative breast cancer
,
T cells
,
mitochondrial biogenesis
,
triple negative breast neoplasms
,
T-lymphocytes
,
deoxyglucose
,
organelle biogenesis
Work type:
Article
Typology:
1.01 - Original Scientific Article
Organization:
MF - Faculty of Medicine
FE - Faculty of Electrical Engineering
Publication status:
Published
Publication version:
Version of Record
Year:
2022
Number of pages:
30 str.
Numbering:
Vol. 14, iss. 5, art. 1343
PID:
20.500.12556/RUL-137225
UDC:
618.19-006
ISSN on article:
2072-6694
DOI:
10.3390/cancers14051343
COBISS.SI-ID:
100035587
Publication date in RUL:
07.06.2022
Views:
1031
Downloads:
133
Metadata:
Cite this work
Plain text
BibTeX
EndNote XML
EndNote/Refer
RIS
ABNT
ACM Ref
AMA
APA
Chicago 17th Author-Date
Harvard
IEEE
ISO 690
MLA
Vancouver
:
Copy citation
Share:
Record is a part of a journal
Title:
Cancers
Shortened title:
Cancers
Publisher:
MDPI
ISSN:
2072-6694
COBISS.SI-ID:
517914137
Licences
License:
CC BY 4.0, Creative Commons Attribution 4.0 International
Link:
http://creativecommons.org/licenses/by/4.0/
Description:
This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Licensing start date:
05.03.2022
Projects
Funder:
ARRS - Slovenian Research Agency
Project number:
P1-0055
Name:
Biofizika polimerov, membran, gelov, koloidov in celic
Funder:
ARRS - Slovenian Research Agency
Project number:
I0-0022
Name:
Mreža raziskovalnih infrastrukturnih centrov Univerze v Ljubljani (MRIC UL)
Funder:
ARRS - Slovenian Research Agency
Funding programme:
MRIC UL IP-0510 BMCM Infrastructure program
Funder:
ARRS - Slovenian Research Agency
Funding programme:
MRIC UL IP-0510 FE Infrastructure program
Funder:
ARRS - Slovenian Research Agency
Funding programme:
Young researchers
Funder:
ARRS - Slovenian Research Agency
Project number:
J3-6794
Name:
Celična energijska presnova kot tarča za zdravljenje raka – genski in farmakološki pristop
Funder:
ARRS - Slovenian Research Agency
Project number:
J7-7424
Name:
Analiza možnih škodljivih učinkov nanodelcev in spremljajočih mehanizmov – od fizikalno-kemijske ter in vitro karakterizacije do aktivacije prirojenega imunskega sistema
Funder:
ARRS - Slovenian Research Agency
Project number:
P3-0067
Name:
Farmakologija in farmakogenomika
Funder:
ARRS - Slovenian Research Agency
Project number:
P3-0427
Name:
Sistemski pristopi k raziskavam človeškega genoma za personalizirano medicino kroničnih imunskih bolezni
Funder:
Other - Other funder or multiple funders
Funding programme:
Ministry of Education, Science and Sport
Project number:
C3330-19-952026
Funder:
ARRS - Slovenian Research Agency
Project number:
P3-0108
Name:
Diferenciacija urotelijskih celic
Similar documents
Similar works from RUL:
Similar works from other Slovenian collections:
Back